Filing Analysis
Verastem, Inc. has amended its existing Note Purchase Agreement to restructure its debt into two series: 'Initial Notes' and new 'Revenue Notes.' The amendment introduces a revenue-sharing component where investors receive a percentage of net sales from avutometinib and defactinib, effectively creating a royalty-based financing structure.
🚩 Red Flags
- Highly punitive redemption terms: The 'Cap Amount' for early redemption can reach 185% of the principal, creating a massive potential liability.
- Revenue-based financing (royalty debt) is often used by companies with limited access to traditional capital markets or facing liquidity constraints.
- Contingent Make-Whole Payment: If sales targets aren't met by 2031, the company must pay back the full principal in cash, creating a 'cliff' risk.
- Security interest on all intellectual property (IP) is a high-stakes collateral for the lenders.
📋 Key Facts
- Amendment No. 3 to Note Purchase Agreement entered into on August 6, 2026.
- Establishes 'Revenue Notes' with an aggregate purchase price of up to $75.0 million.
- Initial tranche of $50.0 million in Revenue Notes scheduled for issuance on August 28, 2026.
- A second $25.0 million tranche is optional, contingent on worldwide net sales of avutometinib and defactinib exceeding $40.0 million in the prior quarter.
- Revenue Notes feature a quarterly payment equal to 4.50% of net sales (initially).
- If total revenue payments do not reach 100% of the funded amount by December 31, 2031, a 'Contingent Make-Whole Payment' is required.
- Redemption penalties are significant: up to 185% of the Funded Amount (the 'Cap Amount') if redeemed after the third anniversary of the Second Purchase Date.
- Notes are secured by a first-priority security interest on substantially all company assets, including intellectual property.
Verastem, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Filing date: August 6, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial results and operations.
Verastem, Inc. is discontinuing its RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following interim data evaluation. The company intends to pivot resources toward the development of VS-7375, an oral KRAS G12D inhibitor.
🚩 Red Flags
- Discontinuation of a clinical trial program represents a loss of R&D progress and potential setback for the company's pipeline value.
- Poor efficacy (9.5% ORR) in the previously treated patient cohort within the doublet combination group.
📋 Key Facts
- Discontinuation of RAMP 203 clinical trial effective December 29, 2025.
- Interim data for doublet combination (treatment-naïve) showed a 40% ORR and median PFS of 11.1 months in 30 patients.
- Interim data for doublet combination (previously treated with G12C inhibitor) showed a low 9.5% ORR and median PFS of 3.7 months in 21 patients.
- The company is shifting strategic focus to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor.
- No dose-limiting toxicities were observed in the evaluated cohorts.
Verastem, Inc. announced the departure of its Chief Operating Officer, Matthew Ros, effective December 19, 2025. The company has entered into a separation agreement providing severance benefits including nine months of salary and COBRA coverage.
🚩 Red Flags
- Executive turnover in a micro-cap/biotech environment can sometimes signal internal friction or strategic shifts, though no specific cause is cited here.
📋 Key Facts
- Matthew Ros departed from his role as Chief Operating Officer on December 19, 2025.
- The Company entered into a Separation Agreement with Mr. Ros on December 19, 2025.
- Severance includes nine months of base salary continuation.
- Severance includes coverage for COBRA health and dental premiums for nine months (or until new employment eligibility).
- A pro-rated bonus will be paid based on actual company performance.
Verastem, Inc. entered into an underwriting agreement to conduct a public offering of common stock and pre-funded warrants. The offering is expected to generate approximately $96.9 million in net proceeds.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 10 million new shares and nearly 3.9 million warrants.
- Use of pre-funded warrants is a common mechanism in micro-cap financing to bypass certain ownership restrictions, often indicating high demand from institutional investors but significant future dilution.
📋 Key Facts
- Underwriters: Jefferies LLC and Guggenheim Securities, LLC.
- Common Stock Offering: 8,543,794 firm shares plus 1,862,069 option shares (exercised in full on Nov 14, 2025).
- Pre-Funded Warrants: Up to 3,870,000 warrants being offered.
- Offering Price: $7.25 per share; $7.2499 per pre-funded warrant.
- Expected Net Proceeds: Approximately $96.9 million after discounts and expenses.
- Closing Date: Expected on or about November 17, 2025.
- Warrant Terms: Exercise price of $0.0001; no expiration date; subject to ownership limits (4.99%, 9.99%, or up to 19.99%).
Verastem, Inc. filed an 8-K to report its financial results for the quarter ended September 30, 2025 and updated its corporate presentation.
📋 Key Facts
- Reported quarterly financial results for the period ending September 30, 2025 (Item 2.02).
- Updated corporate presentation was posted to the company website (Item 7.01).
- Filing date: November 4, 2025.
Verastem, Inc. announced preliminary Phase 1/2a clinical data for its KRAS G12D inhibitor, VS-7375, showing no dose-limiting toxicities at the 400 mg and 600 mg daily doses. The company also reported early efficacy signals with four out of five evaluable patients experiencing tumor reduction.
📋 Key Facts
- VS-7375 monotherapy (400 mg QD and 600 mg QD) showed no dose-limiting toxicities (DLTs).
- Safety profile in PDAC and NSCLC patients was consistent with previously reported data from partner GenFleet Therapeutics.
- Four out of five efficacy-evaluable patients have experienced tumor reduction and remain on treatment.
- Company has initiated patient enrollment for a combination cohort evaluating VS-7375 with cetuximab.
- Interim safety and efficacy update is expected in the first half of 2026.
Verastem, Inc. announced updated Phase 1/2 monotherapy study data for VS-7375 in patients with advanced KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC). The data was presented by their partner, GenFleet Therapeutics, at the ESMO 2025 congress.
🚩 Red Flags
- No significant red flags identified in this clinical data update.
📋 Key Facts
- Study population: 66 patients with advanced KRAS G12D mutant PDAC; 59 were heavily pre-treated (≥2 prior lines of therapy).
- Overall Response Rate (ORR): 40.7% (24/59) in efficacy-evaluable patients.
- Disease Control Rate (DCR): 96.7% (57/59).
- Median Progression-Free Survival (PFS): 5.52 months; 4-month PFS rate of 78.2%.
- Overall Survival (OS) at month four: 92.2%; median OS not yet reached.
- Safety profile: Grade 3 TRAEs occurred in 30.3% of patients; one Grade 4 event (neutropenia). No TRAE-related deaths reported.
Verastem, Inc. filed an 8-K to furnish an updated corporate presentation on its website as of September 8, 2025.
📋 Key Facts
- The company posted an updated corporate presentation (Exhibit 99.1) on its website.
- Filing date: September 8, 2025.
- The filing is made pursuant to Item 7.01 Regulation FD Disclosure.
Verastem, Inc. announced updated Phase 1/2 clinical data for its partner's drug candidate VS-7375 (GFH375) in patients with advanced KRAS G12D mutant solid tumors conducted in China. The data shows positive efficacy signals in NSCLC and a manageable safety profile.
🚩 Red Flags
- None identified in this clinical data update.
📋 Key Facts
- Data cutoff date: July 15, 2025; Median follow-up: 4.5 months.
- NSCLC cohort (at 600mg dose): Overall Response Rate (ORR) of 68.8% and Disease Control Rate (DCR) of 93.8%.
- Total NSCLC evaluable patients (all doses): ORR of 57.7% and DCR of 88.5%.
- Safety: Grade 3+ treatment-related adverse events occurred in 7.7% of the total study population.
- No TRAE-related deaths were reported among the 142 patients evaluated.
Verastem, Inc. filed an 8-K to furnish its investor webcast presentation dated June 2, 2025, as part of a Regulation FD disclosure.
📋 Key Facts
- The filing is primarily used to provide access to the company's investor webcast presentation (Exhibit 99.1).
- Report date: June 2, 2025.
- The company is listed on the Nasdaq Capital Market under ticker VSTM.
Verastem, Inc. announced updated Phase 1 clinical data for its drug candidate VS-7375 (GFH375) in patients with advanced KRAS G12D mutant solid tumors. The data shows positive efficacy signals and a manageable safety profile, leading to an upcoming presentation at the ASCO Annual Meeting.
🚩 Red Flags
- Clinical data is based on a small sample size (n=35 for efficacy-evaluable patients across two tumor types).
📋 Key Facts
- Phase 1 study conducted by partner GenFleet Therapeutics in China included 62 enrolled patients.
- In pancreatic ductal adenocarcinoma (n=23), ORR was 52% and DCR was 100%.
- In non-small cell lung cancer (n=12), ORR was 42% and DCR was 83%.
- No dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD).
- Treatment-related adverse events (TRAEs) were mostly Grade 1/2; no TRAE-related deaths reported.
- A Phase 1/2a study will be conducted in the U.S. to evaluate safety and efficacy in advanced solid tumors.
Verastem, Inc. held its 2025 annual meeting of stockholders and reported positive updated safety and efficacy data from the RAMP 205 clinical trial for metastatic pancreatic cancer. The company also announced plans to develop a registrational Phase 3 trial starting in 2026.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 22, 2025; Class I Directors (John Johnson, Michael Kauffman, Eric Rowinsky) were elected until 2028.
- Ernst & Young LLP was ratified as the independent registered public accounting firm.
- Stockholders approved executive compensation in a non-binding advisory vote.
- RAMP 205 Phase 1/2 trial data: Dose level 1 showed an 83% partial response rate (10/12 patients).
- Across all five dose cohorts, 92% of efficacy evaluable patients showed tumor reduction as best response.
- Company plans to begin a registrational Phase 3 front-line metastatic PDAC trial in 2026.
Verastem, Inc. announced that the FDA has granted accelerated approval for its AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules and defactinib tablets) for treating adult patients with recurrent KRAS mt low-grade serous ovarian cancer (LGSOC). The approval is based on tumor response rates, though continued approval may depend on confirmatory clinical trials.
🚩 Red Flags
- Accelerated approval requires successful completion of confirmatory trials to maintain market authorization.
📋 Key Facts
- FDA granted accelerated approval for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets).
- Indication: Treatment of adult patients with recurrent KRAS mt low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.
- Approval is based on tumor response rate and duration of response.
- Continued approval is contingent upon verification of clinical benefit in a confirmatory trial.
Verastem, Inc. entered into a Securities Purchase Agreement to conduct a $75 million private placement of common stock and pre-funded warrants. The proceeds are intended to fund clinical development and the potential launch of avutometinib and defactinib.
🚩 Red Flags
- Significant potential dilution for existing shareholders due to the issuance of common stock and a large number of pre-funded warrants.
- Pre-funded warrants effectively act as delayed equity issuance that will trigger further dilution upon exercise.
📋 Key Facts
- Private placement expected to raise approximately $75 million in gross proceeds.
- Sale of 3,429,287 shares of common stock at $7.00 per share.
- Issuance of 7,285,713 pre-funded warrants at $6.9999 per warrant (exercise price of $0.0001 per share).
- Expected closing date is April 28, 2025.
- Registration statement to be filed by May 28, 2025, with an effectiveness goal by July 27, 2025.
- Placement agents include Guggenheim Securities, BTIG, Mizuho Securities USA, B. Riley Securities, and RBC Capital Markets.
Verastem, Inc. filed an 8-K to furnish its updated corporate presentation dated March 20, 2025, pursuant to Regulation FD.
📋 Key Facts
- The company updated its corporate presentation on its website.
- The presentation is furnished as Exhibit 99.1.
- Filing date: March 20, 2025.
Verastem, Inc. announced the exercise of an option under its existing collaboration agreement with GenFleet Therapeutics to acquire rights for VS-7375, a KRAS G12D inhibitor. The company also updated its corporate presentation.
📋 Key Facts
- On January 14, 2025, the Company exercised its option regarding VS-7375.
- VS-7375 is an oral and selective KRAS G12D (ON/OFF) inhibitor.
- The rights acquired include exclusive development and commercialization worldwide outside of mainland China, Hong Kong, Macau, and Taiwan.
- The option was part of a collaboration agreement entered into in August 2023 with GenFleet Therapeutics (Shanghai), Inc.
Verastem, Inc. announced the appointment of Matthew E. Ros as Chief Operating Officer, effective January 14, 2025. The filing details his professional background in biotechnology and the specific terms of his employment agreement.
📋 Key Facts
- Matthew E. Ros appointed as Chief Operating Officer effective January 14, 2025.
- Annual base salary set at $485,000 with a target annual bonus of 45% of base salary.
- Equity compensation includes 50,000 RSUs vesting over four years and 33,333 milestone-based RSUs.
- Severance package includes nine months of base salary and COBRA premium coverage if terminated without cause or for good reason.
Verastem, Inc. entered into a $150 million Note Purchase Agreement with Oberland Capital Management LLC and affiliates to secure up to $75M in immediate funding (netting $32.3M after debt repayment) and additional tranches tied to FDA milestones and sales targets. The deal includes a revenue participation component where investors receive 1% of net sales from the first $100M of 'Included Products'.
🚩 Red Flags
- High-cost financing: Includes a revenue participation component (royalty-like) on top of interest.
- Significant dilution/liquidity event: $75M in debt and direct equity sale to the same group.
- Heavy security: Notes are secured by substantially all company assets, including core IP.
- Complex repayment terms: Redemption amounts include significant premiums (up to 195% of principal) if redeemed early.
📋 Key Facts
- Entered into Note Purchase Agreement with RGCM SA LLC (Purchaser Agent) and Oberland Capital Management LLC.
- Total potential notes: $150.0 million ($75M initial, $25M upon FDA approval for LGSOC, $50M if sales >$55M).
- Initial sale of $75.0 million resulted in net proceeds of ~$32.3 million after repaying Oxford Loan Agreement.
- Interest rate: Term SOFR + 3.71% (capped at 9.75%).
- Revenue Participation: Investors receive 1.00% of the first $100M in annual net sales of 'Included Products' (up to 2.00% max).
- Stock Purchase Agreement: Investors purchased 1,416,939 shares at $5.2931 per share.
- The notes are secured by a security interest on substantially all company assets and intellectual property.
- FDA Priority Review for avutometinib/defactinib combination in LGSOC with PDUFA date of June 30, 2025.
Verastem, Inc. presented updated mature data from its Phase 2 RAMP 201 clinical trial at the IGCS 2024 Annual Meeting. The filing also provides updates regarding the company's rolling New Drug Application (NDA) submission to the FDA for its combination therapy.
📋 Key Facts
- Presented mature data from Phase 2 RAMP 201 trial evaluating avutometinib and defactinib in recurrent low-grade serous ovarian cancer.
- Data presented at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting on October 17, 2024.
- Provided an update on the status of a rolling New Drug Application (NDA) submission to the FDA.
- Released investor presentation and press release detailing trial results.
Verastem, Inc. entered into an underwriting agreement to conduct a significant public offering of common stock, warrants, and pre-funded warrants. The offering aims to raise approximately $51.1 million in net proceeds to fund company operations.
🚩 Red Flags
- Significant dilution risk due to the issuance of over 13.3 million new shares and up to 18.3 million total potential shares via warrants/pre-funded warrants.
- Warrant exercise price ($3.50) is higher than the current offering price ($3.00), indicating potential immediate dilution upon conversion if stock price rises.
📋 Key Facts
- Offering size: 13,333,334 shares of Common Stock with accompanying Warrants, plus up to 5,000,000 Pre-Funded Warrants.
- Combined offering price for Common Stock and Warrant: $3.00 per share.
- Pre-Funded Warrant price: $2.999 per share (effectively $0.001 exercise price).
- Warrant terms: Exercise price of $3.50, expiring 18 months from issuance.
- Expected net proceeds: Approximately $51.1 million.
- Underwriters: Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
- Closing date expected on or about July 25, 2024.
Verastem, Inc. announced the initiation of a rolling NDA submission to the FDA for its combination therapy (avutometinib and defactinib) targeting recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company also provided detailed market opportunity estimates and an update on its GenFleet collaboration.
🚩 Red Flags
- Significant reliance on interim clinical data and extrapolated 'mean duration of therapy' which may change with mature data.
- Market estimates are based on small, rare patient populations (approx. 500-1,000 annual incidence) where prevalence is difficult to establish precisely.
📋 Key Facts
- Initiated rolling NDA submission to the FDA for avutometinib + defactinib in LGSOC.
- Seeking accelerated approval; plans to request priority review of the NDA.
- Estimated annual addressable market: $300M (KRAS mt) and $270M (KRAS wt).
- Estimated total prevalent market opportunity: $1.7B (KRAS mt) and $1.1B (KRAS wt).
- Assumed therapy cost: $34,000 per month.
- GenFleet collaboration update: First patient dosed in Phase 1/2 trial for GFH375/VS-7375 in China (July 2024).
Verastem, Inc. filed an 8-K to furnish an updated corporate presentation via Exhibit 99.1. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The company updated its corporate presentation on June 26, 2024.
- The update was posted to the company's website as part of a Regulation FD disclosure.
- No material financial changes or structural shifts were reported in this specific filing.
Verastem, Inc. has initiated a rolling submission of a New Drug Application (NDA) to the FDA for the accelerated approval of avutometinib and defactinib in treating recurrent KRAS mutant low-grade serious ovarian cancer (LGSOC). The company plans to request priority review for this application.
🚩 Red Flags
- Potential requirement for a companion diagnostic test, which could delay or prevent marketing approval if not successfully validated/approved.
- Revenue and market size estimates are highly speculative and dependent on physician adoption, reimbursement, and patient access.
- Risk that the FDA may approve the drug for a narrower patient population than anticipated.
📋 Key Facts
- Initiated rolling NDA submission for avutometinib + defactinib combination for recurrent KRAS mt LGSOC.
- The FDA has previously granted Orphan Drug and Breakthrough Therapy Designations for this combination in LGSOC.
- RAMP-201 trial data (as of Feb 2024 cutoff) showed a confirmed objective response rate (ORR) of 27% in all patients, with 37% in KRAS mt patients.
- Clinical Benefit Rate (CBR ≥ 6 months) was 60% among evaluable patients.
- The company plans to request priority review for the NDA.
- Management estimates KRAS mt population represents over two-thirds of the revenue opportunity.
Verastem, Inc. held its 2024 annual meeting of stockholders, resulting in the election of Class III directors and ratification of Ernst & Young LLP as independent auditors. The company also released interim safety and efficacy results from its RAMP 205 clinical trial for pancreatic cancer.
🚩 Red Flags
- Clinical trial safety concerns: 12 patients experienced 19 treatment-emergent SAEs, including sepsis and pulmonary embolism.
- Two patients discontinued treatment due to treatment-emergent adverse events (febrile neutropenia, blood bilirubin increased, and retinal pigment epithelium detachment).
📋 Key Facts
- Annual Meeting held on May 23, 2024; stockholders elected four Class III directors: Paul Bunn, Anil Kapur, Daniel Paterson, and Michelle Robertson.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the current fiscal year.
- Interim RAMP 205 trial data (as of May 14, 2024) showed an 83% partial response rate in the dose level 1 cohort (5/6 patients).
- In all cohorts where scans were available, 21 out of 26 patients experienced a reduction in target lesion diameter.
- Reported 19 treatment-emergent serious adverse events (SAEs) among 41 treated patients.
Verastem, Inc. filed an 8-K to furnish a corporate presentation updated as of April 9, 2024. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The company posted its updated corporate presentation on its website on April 9, 2024.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation is included as Exhibit 99.1.
Verastem, Inc. issued a press release via Form 8-K to outline its strategic priorities and upcoming clinical/business catalysts for the year 2024.
📋 Key Facts
- The filing is an Item 7.01 Regulation FD Disclosure.
- The company released a press statement on January 29, 2024, detailing 2024 strategic priorities and upcoming catalysts.
- The primary purpose of the filing is to furnish the press release as Exhibit 99.1.
Verastem, Inc. held a Special Meeting of Stockholders on January 17, 2024, to vote on a proposal regarding an option exchange for certain insiders. The stockholders narrowly approved the one-time exchange of options held by executive officers, employees, and non-employee directors.
🚩 Red Flags
- Extremely narrow margin of victory on an insider compensation/equity structure change (approx. 51.7% in favor).
📋 Key Facts
- Special Meeting held on January 17, 2024, in Needham, MA.
- Total shares entitled to vote: 25,268,102.
- Shares represented at meeting (in person or proxy): 16,016,215.
- Proposal No. 1 (Option Exchange) passed with 8,197,712 votes in favor and 7,793,121 votes against.
- The proposal involved a one-time exchange of certain options for executive officers, employees, and non-employee directors.
Verastem, Inc. has amended its existing Loan and Security Agreement with Oxford Finance LLC. The amendment primarily extends the deadline for drawing down the Term C Loan by one year.
🚩 Red Flags
- Extension of loan draw period suggests the company may be delaying capital infusion or managing liquidity constraints by pushing back debt obligations/drawdowns.
📋 Key Facts
- Date of event: January 4, 2024.
- The Company amended its March 25, 2022, Loan and Security Agreement with Oxford Finance LLC (collateral agent/lender).
- The amendment extends the outside date for drawing the Term C Loan from March 31, 2024, to March 31, 2025.
- The amendment is filed under Items 1.01 and 2.03.